


EN2-DGCG



Trial setting: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

Study Design:



Sponsor(s): NSGO


Planned No. of patients: 240

Current accrual: 183

Other important information: Status - recruiting



Ongoing Trials – status update



EN2-DGCG



Group	PI	Country	No. of Institutions	Activated	Total no of pts randomized	
					Sept 2016	Sept 2017
DGCG	Mirza	Denmark	6	6	53	58
NSGO	Lundgren	Sweden	4	4	26	30
		Finland	6	5	5	8
BGOG	Kridelka	Belgium	10	8	8	8
EORTC	Amant	Belgium	4	4	3	3
		Austria	1	1	1	1
		Germany	4	4	5	9
		Spain	4	4	12	15
		UK	9	9	18	30
		Netherlands	4	4	1	2
		Czech Rep.	1	1	4	5
C-GOG (MDACC)	Soliman	US	1	1	1	1
MaNGO	Ferrero	Italy	6	1	1	3
MITO	Greggi	Italy	7	1	2	4
GEICO	Santabella	Spain	10	5	2	5
CEEGOG	Cibula	Czech Rep.	5	0	0	0
ISGO	Levy	Israel	7	0	0	0
NOGGO	Sehouli	Germany	5	0	0	0
Total			94	58	142	182